Edition:
United Kingdom

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

37.99USD
8:59pm GMT
Change (% chg)

$1.15 (+3.12%)
Prev Close
$36.84
Open
$36.97
Day's High
$38.26
Day's Low
$36.75
Volume
354,134
Avg. Vol
312,726
52-wk High
$38.26
52-wk Low
$15.15

Select another date:

Fri, Jan 12 2018

UPDATE 1-U.S. FDA approves expanded use of AstraZeneca cancer drug

Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

BRIEF-Myriad Genetics posts Q1 adjusted earnings per share $0.26

* Myriad Genetics reports fiscal first-quarter 2018 financial results

BRIEF-Myriad announces GeneSight Psychotropic results from a large prospective trial in patients with major depressive disorder

* Myriad announces GeneSight® Psychotropic results from a large prospective trial in patients with major depressive disorder

BRIEF-‍Myriad Genetics announces new positive results for EndoPredict

* Endopredict (epclin) shown in second study to be more effective than oncotype dx® (rs) in women with intermediate risk of breast cancer recurrence

BRIEF-Myriad submits BRACAnalysis® CDx application for regulatory approval in Japan

* Myriad submits BRACAnalysis® CDX application for regulatory approval in Japan for HER2- metastatic breast cancer

BRIEF-Myriad Genetics’s supplementary PMA for BRACAnalysis CDx accepted by FDA for review

* Myriad’s BRACAnalysis CDx supplementary pma accepted by fda for review as a companion diagnostic for Lynparza (olaparib) in metastatic breast cancer

BRIEF-Myriad Genetics Inc announces launch of riskScore

* Myriad Genetics Inc - September 5, co announced it has launched riskScore - SEC filing Source text: (http://bit.ly/2eDj2Kj) Further company coverage:

BRIEF-EndoPredict receives positive coverage decisions from Medicare and Anthem

* EndoPredict receives positive coverage decisions from Medicare and Anthem

BRIEF-Myriad Genetics Q4 adjusted earnings per share $0.30

* Myriad Genetics reports fiscal fourth-quarter 2017 and fiscal full-year 2017 financial results

Select another date: